Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL BARAM

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1700863628
CMS profile
349964
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$25.18

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $25.18 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $25.18 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL BARAM

NPI 1700863628 · CMS profile ID 349964

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700863628?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL BARAM, NPI 1700863628, CMS profile ID 349964. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700863628?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MICHAEL BARAM, NPI 1700863628, CMS profile ID 349964. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700863628?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MICHAEL BARAM, NPI 1700863628, CMS profile ID 349964, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1700863628?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $25.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $25.1808/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944828157 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $25.18 1
PY2023 $44.97 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $13,833.68 12
PY2024 Recipient $3,834.24 4
PY2024 Principal investigator $125,066.50 73
PY2023 Principal investigator $22,750.00 5
PY2021 Principal investigator $69,102.00 8
PY2020 Principal investigator $269,809.50 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

77 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Octapharma USA, Inc. $178.81 12/24/2024 Covered Recipient Physician Atenativ No dispute reported 06/30/2026 1142314002
Principal investigator 1 Abbott Laboratories $9.34 12/20/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172277
Principal investigator 1 Abbott Laboratories $111.76 12/18/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172275
Principal investigator 1 Abbott Laboratories $154.49 12/10/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172267
Principal investigator 1 Abbott Laboratories $10.58 12/10/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172269
Principal investigator 1 Abbott Laboratories $4.59 12/10/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172271
Principal investigator 1 Abbott Laboratories $3.37 12/10/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172273
Principal investigator 1 Abbott Laboratories $21,800.00 11/08/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population No dispute reported 06/30/2026 1146171889
Principal investigator 1 Abbott Laboratories $115.70 10/30/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172263
Principal investigator 1 Abbott Laboratories $176.66 10/30/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172265
Principal investigator 1 Abbott Laboratories $0.69 10/18/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172257
Principal investigator 1 Abbott Laboratories $30.56 10/18/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172259
Principal investigator 1 Abbott Laboratories $14.30 10/18/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172261
Principal investigator 1 Abbott Laboratories $139.25 10/09/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172255
Recipient Octapharma USA, Inc. $396.43 09/06/2024 Covered Recipient Physician Atenativ No dispute reported 06/30/2026 1142313991
Recipient Octapharma USA, Inc. $2,263.90 09/06/2024 Covered Recipient Physician Atenativ No dispute reported 06/30/2026 1142313995
Recipient Octapharma USA, Inc. $995.10 09/06/2024 Covered Recipient Physician Atenativ No dispute reported 06/30/2026 1142313997
Principal investigator 1 Abbott Laboratories $85.32 08/07/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172253
Principal investigator 1 Abbott Laboratories $356.28 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172167
Principal investigator 1 Abbott Laboratories $208.20 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172169
Principal investigator 1 Abbott Laboratories $138.80 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172171
Principal investigator 1 Abbott Laboratories $138.80 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172173
Principal investigator 1 Abbott Laboratories $1,040.37 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172175
Principal investigator 1 Abbott Laboratories $458.00 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172177
Principal investigator 1 Abbott Laboratories $458.00 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172179
Principal investigator 1 Abbott Laboratories $838.00 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172181
Principal investigator 1 Abbott Laboratories $480.00 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172183
Principal investigator 1 Abbott Laboratories $480.00 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172185
Principal investigator 1 Abbott Laboratories $10,574.04 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172187
Principal investigator 1 Abbott Laboratories $10,574.04 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172189
Principal investigator 1 Abbott Laboratories $10,574.04 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172191
Principal investigator 1 Abbott Laboratories $1,228.18 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172193
Principal investigator 1 Abbott Laboratories $1,228.18 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172195
Principal investigator 1 Abbott Laboratories $667.31 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172197
Principal investigator 1 Abbott Laboratories $25.07 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172199
Principal investigator 1 Abbott Laboratories $670.28 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172201
Principal investigator 1 Abbott Laboratories $570.93 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172203
Principal investigator 1 Abbott Laboratories $10,629.72 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172205
Principal investigator 1 Abbott Laboratories $10,629.72 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172207
Principal investigator 1 Abbott Laboratories $10,629.72 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172209
Principal investigator 1 Abbott Laboratories $949.34 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172211
Principal investigator 1 Abbott Laboratories $625.32 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172213
Principal investigator 1 Abbott Laboratories $238.24 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172215
Principal investigator 1 Abbott Laboratories $73.29 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172217
Principal investigator 1 Abbott Laboratories $30.05 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172219
Principal investigator 1 Abbott Laboratories $14.65 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172221
Principal investigator 1 Abbott Laboratories $85.32 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172223
Principal investigator 1 Abbott Laboratories $131.96 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172225
Principal investigator 1 Abbott Laboratories $32.26 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172227
Principal investigator 1 Abbott Laboratories $77.96 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172229
Principal investigator 1 Abbott Laboratories $269.64 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172231
Principal investigator 1 Abbott Laboratories $7.19 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172233
Principal investigator 1 Abbott Laboratories $0.35 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172235
Principal investigator 1 Abbott Laboratories $0.02 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172237
Principal investigator 1 Abbott Laboratories $10.04 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172239
Principal investigator 1 Abbott Laboratories $19.81 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172241
Principal investigator 1 Abbott Laboratories $9.90 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172243
Principal investigator 1 Abbott Laboratories $49.52 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172245
Principal investigator 1 Abbott Laboratories $17.58 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172247
Principal investigator 1 Abbott Laboratories $6.23 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172249
Principal investigator 1 Abbott Laboratories $7.32 07/24/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT ACTpro Cartridge using Venous and Arterial Whole Blood Specimens on the i-STAT 1 Analyzer in an Adult Population (the Protocol) No dispute reported 06/30/2026 1146172251
Principal investigator 1 Dompe Farmaceutici S.p.A. $21.94 07/24/2024 Non-covered Recipient Entity
Thomas Jefferson University
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154460772
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,984.50 07/24/2024 Non-covered Recipient Entity
Thomas Jefferson University
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154460774
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,626.76 07/24/2024 Non-covered Recipient Entity
Thomas Jefferson University
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154460776
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,464.08 07/24/2024 Non-covered Recipient Entity
Thomas Jefferson University
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154460778
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,713.15 07/24/2024 Non-covered Recipient Entity
Thomas Jefferson University
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154460780
Principal investigator 1 Dompe Farmaceutici S.p.A. $750.00 06/19/2024 Non-covered Recipient Entity
Thomas Jefferson University
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154460794
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,035.00 06/19/2024 Non-covered Recipient Entity
Thomas Jefferson University
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154460796
Principal investigator 1 Dompe Farmaceutici S.p.A. $3,000.00 06/19/2024 Non-covered Recipient Entity
Thomas Jefferson University
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154460798
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,661.56 06/05/2024 Non-covered Recipient Entity
Thomas Jefferson University
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154460788
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,506.60 06/05/2024 Non-covered Recipient Entity
Thomas Jefferson University
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154460790
Principal investigator 1 Dompe Farmaceutici S.p.A. $877.50 06/05/2024 Non-covered Recipient Entity
Thomas Jefferson University
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154460792
Principal investigator 1 Dompe Farmaceutici S.p.A. $750.00 04/03/2024 Non-covered Recipient Entity
Thomas Jefferson University
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154460782
Principal investigator 1 Dompe Farmaceutici S.p.A. $2,760.00 04/03/2024 Non-covered Recipient Entity
Thomas Jefferson University
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154460784
Principal investigator 1 Dompe Farmaceutici S.p.A. $8,000.00 04/03/2024 Non-covered Recipient Entity
Thomas Jefferson University
"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" No dispute reported 06/30/2026 1154460786
Principal investigator 1 Abbott Laboratories $4.98 02/22/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT hs-Tnl Test to Aid in the Diagnosis of Myocardial Infarction (MI) No dispute reported 06/30/2026 1146170303
Principal investigator 1 Abbott Laboratories $0.15 02/22/2024 Non-covered Recipient Entity
Jefferson Medical College at Thomas Jefferson University
Clinical Evaluation of the i-STAT hs-Tnl Test to Aid in the Diagnosis of Myocardial Infarction (MI) No dispute reported 06/30/2026 1146170305